摘要
为改善干扰素α-2a(IFN α-2a)的药代动力学特性并提高其疗效,开发了一种皮下注射的聚乙二醇化新产品,即聚乙二醇化干扰素α-2a(PEGIFN α-2a)。PEG IFN α-2a每周1次给药与:IFN α-2a每周3次给药相比,治疗伴或不伴肝硬化的慢性丙型肝炎(CHC)病人,其持久的病毒学应答率(SVR)显著提高。与IFN α-2a单用或IFN α-2b与利巴韦林合用相比,PEGIFN α-2a可更好地改善CHC病人的生活质量。CHC病人对PEG IFN α-2a的耐受性与IFN α-2a相似,头疼、疲劳和肌痛是最常见的药物不良反应。
Peginterferon- α-2a(40ku) is a new 'pegylated' subcutaneous formulation of interferon-α-2a that has been developed to improve on the pharmacokinetic profile and therapeutic efficacy of interferon- α -2a. Peginterferon-α-2a administered once a week produces significantly higher sustained virological responses than interferon- α-2a administered three times weekly in noncirrhotic or cirrhotic patients with chronic hepatitis C. Peginterferon-α-2a produced better than interferon-α-2a alone or interferon-α-2b plus oral ribavirin on various measures of quality of life in patients with chronic hepatitis C. The tolerability profile of peginterferon-α-2a is broadly similar to that of interferon-α-2a in patients with chronic hepatitis C. Headache, fatigue and myalgia are among the most common adverse events.
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
2004年第1期60-63,共4页
The Chinese Journal of Clinical Pharmacology
